Abstract: Described herein are cell culture media and/or cell culture media supplements that comprise at least one GSK3 inhibitor, a ROCK inhibitor, and one or more mitogenic growth factors, and methods of culturing and/or expanding pluripotent stem cells in 3D culture formats in the compositions described herein.

Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.

Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.

Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.

Abstract: A foot splint for the prevention and rehabilitation of plantar fasciitis by maintaining a wearer's foot and, hence, his plantar fascia in a pre-selected amount of dorsiflexion. The foot splint includes a footplate for supporting the wearer's foot, a bracket integrally attached to the footplate near the heel region, where the bracket has at least one ankle angle preset, a strut (either medial, lateral, or both sides) extending along the lower leg of the wearer, a strut sleeve removably enveloping the strut. The sleeve has an upper end and a lower end, and the strut protrudes from the lower end of the sleeves. There is an adjustable leg strap attached to the strut sleeve at the upper end. The strap secures the upper end to the leg of a wearer during operation. A padded insole may be provided to cushion the wearer's foot from the footplate. The foot splint provides a comfortable “slipper-like” feel for the wearer.